Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mediator Is Tip Of EU Parliament's Probe Into EMA; Funding Held In Balance

This article was originally published in The Pink Sheet Daily

Executive Summary

The European Parliament blocks approval of EMA's budget accounts, citing handling of Mediator and broader conflict of interest concerns.

You may also be interested in...

Servier Denies Deceit As French Mediator Trial Begins

A trial has begun in France to investigate the roles of the French firm Servier and the former drug regulator AFSSAPS in the Mediator scandal, where an amphetamine-like drug was kept on the market despite mounting evidence of its cardiac side-effects.

EMA Leadership Goes To Pott After Rasi Retroactively Unhired

Andreas Pott, who helped steer agency through Mediator scandal, becomes acting director again as irregularities in 2011’s recruitment process force departure of Guido Rasi – who himself might still get top job again once hiring process reboots.

Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root

EMA’s plans for access to clinical trials data not set to be ready until well into 2014.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts